Long-term effects of caffeine therapy for apnea of prematurity.

@article{Schmidt2007LongtermEO,
  title={Long-term effects of caffeine therapy for apnea of prematurity.},
  author={Barbara Schmidt and Robin S. Roberts and Peter Graham Davis and Lex William Doyle and Keith James Barrington and Arne Ohlsson and Alfonso J Solimano and Win Tin},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 19},
  pages={
          1893-902
        }
}
BACKGROUND Methylxanthine therapy is commonly used for apnea of prematurity but in the absence of adequate data on its efficacy and safety. It is uncertain whether methylxanthines have long-term effects on neurodevelopment and growth. METHODS We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed. The primary outcome was a composite of death, cerebral palsy, cognitive delay… Expand

Paper Mentions

Interventional Clinical Trial
This is a clinical trial which will investigate whether administration of caffeine, a respiratory stimulant, to preterm babies soon after birth can prevent the need for a… Expand
ConditionsApnea of Prematurity, BPD - Bronchopulmonary Dysplasia, Hemodynamic Instability, (+1 more)
InterventionDrug
Interventional Clinical Trial
In premature infants, apnea of prematurity is one of their major clinical problems. Caffeine is currently a worldwide therapy to reduce the number and severity of these apneas. This… Expand
ConditionsApnea of Prematurity
InterventionOther
Interventional Clinical Trial
Apnea of prematurity is a common condition that is usually treated with methylxanthines. Methylxanthines are adenosine receptor blockers that have powerful influences on the central… Expand
ConditionsApnea of Prematurity
InterventionDrug
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
TLDR
Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminphylline cannot be undermined. Expand
Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity
TLDR
This review of the literature on neonatal methylxanthine therapies found that caffeine is associated with fewer adverse effects and a wider therapeutic window when compared with theophylline, and larger doses of caffeine citrate have been shown to improve acute neonatal outcomes when administered promptly. Expand
Comparison between Caffeine and Theophylline Therapy for Apnea of Prematurity
TLDR
Caffeine was as effective as theophylline in the short­term for reducing apnea in preterm babies and was better tolerated and was easier to administer. Expand
Timing of caffeine therapy in very low birth weight infants.
TLDR
Caffeine therapy was found to reduce the risks of important short-term morbidities such as bronchopulmonary dysplasia and severe retinopathy of prematurity, decrease the incidence of cerebral palsy and cognitive delay at 18 months, and improve gross motor function at 5 years. Expand
Association of early versus late caffeine administration on neonatal outcomes in very preterm neonates
TLDR
In this third large-scale observational study of the Canadian Neonatal Network, Lodha et al. retrospectively investigated the effect of early versus late initiation of caffeine therapy on neonatal short-term outcomes of very preterm infants. Expand
Caffeine: an evidence-based success story in VLBW pharmacotherapy
TLDR
Caffeine has a very favorable benefit-to-risk ratio, and has become one of the most prescribed and cost-effective pharmacotherapies in the NICU, and in particular the most recent studies that have established the safety and efficacy. Expand
Caffeine for Apnea of Prematurity: A Neonatal Success Story
TLDR
Caffeine for Apnea of Prematurity was an international, multicenter, placebo-controlled randomized trial designed to determine whether survival without neurodevelopmental disability at a corrected age of 18 months is improved if apnea of prematurity is managed without methylxanthines in infants at a high risk of apneic attacks. Expand
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
TLDR
Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years. Expand
Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.
TLDR
Therapeutic neonatal caffeine administration has no long-term effects on sleep duration or sleep apnea during childhood, and ex-preterm infants, regardless of caffeine status, are at risk for obstructiveSleep apnea and periodic limb movements in later childhood. Expand
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity
TLDR
This study suggests that doxapram is not associated with an increased risk of ND, and needs to be confirmed or refuted by a large, well-designed, placebo-controlled randomized trial. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight and reduced weight gain temporarily. Expand
Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial
TLDR
The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Expand
Summary Proceedings From the Apnea-of-Prematurity Group
TLDR
A sample framework for the study of apnea in neonates is described and future research needs are identified and undetermined role of AOP affecting long-term neurodevelopmental outcomes is identified. Expand
Methylxanthine treatment for apnea in preterm infants.
TLDR
Methylxanthines are effective in reducing the number of apneic attacks and the use of mechanical ventilation in the two to seven days after starting treatment, and caffeine would be the preferred drug. Expand
Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.
TLDR
Caffeine is an effective pharmacologic respirogenic agent in the preterm infant with apnea and all infants except one showed a significant decrease in the frequency of apneic episodes associated with caffeine therapy. Expand
Severity of Neonatal Retinopathy of Prematurity Is Predictive of Neurodevelopmental Functional Outcome at Age 5.5 Years
TLDR
S Severity of neonatal ROP seems to be a marker for functional disability at age 5.5 years among very low birth weight survivors who had threshold ROP, particularly if they have unfavorable visual acuity. Expand
Prospective Evaluation of Postnatal Steroid Administration: A 1-Year Experience From the California Perinatal Quality Care Collaborative
TLDR
The common early use of hydrocortisone for hypotension and the high morbidity and mortality in children receiving such treatment has not been recognized previously and prospective trials evaluating the short- and long-term risk/benefit of such treatment are urgently required. Expand
Controversies surrounding xanthine therapy.
TLDR
An international controlled clinical trial is underway to examine the long-term efficacy and safety of methylxanthine therapy in very low birth weight babies. Expand
Apnoea of prematurity.
Idiopathic apnoea of prematurity is a common and troublesome disorder which requires therapeutic intervention to avoid potential morbidity in premature infants who require neonatal intensive care.Expand
Caffeine for apnea of prematurity.
Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with anExpand
...
1
2
3
4
5
...